Press release
Metastatic Uveal Melanoma Market to Observe Stupendous Growth During the Forecast Period - DelveInsight | Key Companies - Delcath Systems, Versastem Oncology, BioMedValley Discoveries, Pfizer, and Others
Metastatic Uveal Melanoma Market
The Metastatic Uveal Melanoma market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of opportunities and assess the underlying potential of the market.
Metastatic Uveal Melanoma: An Overview
Uveal melanoma, also known as intraocular melanoma is the most common malignancy in adults, representing ∼85% of ocular melanomas. It is considered rare cancer that arises from melanocytes located anywhere in the uveal tract. Approximately 85%-90% of cases involve the choroid(larger tumor), while those remaining are localized to the iris(small tumor) or ciliary body(large tumor). It is usually initiated by a mutation in GNAQ or GNA11.
Metastatic Uveal Melanoma Market Key Facts
As per Ahmad et al. (2021), the overall age-standardized incidence rate (ASIR) of uveal melanoma in Germany was 6.41 persons per million.
As per the study by Neumann et al. (2019), the incidence of uveal melanoma in Europe was found to be approximately 6 per million.
As per a study by Vidal et al. (2020), in Spain, the incidence of Uveal melanoma ranges from 5.3 to 10.9 cases per million inhabitants per year.
Find a sample copy of the Metastatic Uveal Melanoma Market report at:
https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Uveal Melanoma Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Metastatic Uveal Melanoma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Metastatic Uveal Melanoma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Request a sample and discover more about the report offerings @
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Uveal Melanoma Epidemiology
The epidemiology section covers detailed insights into the historical and current Metastatic Uveal Melanoma patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032.
Explore more about the Metastatic Uveal Melanoma Epidemiology @
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Uveal Melanoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Metastatic Uveal Melanoma market or expected to get launched in the market during the study period. The analysis covers Metastatic Uveal Melanoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Report's Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Metastatic Uveal Melanoma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for a sample report to understand more about the Metastatic Uveal Melanoma pipeline development activities @
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Metastatic Uveal Melanoma Therapeutics Assessment
Some of the key companies in the Metastatic Uveal Melanoma Market include
Delcath Systems
Versastem Oncology
BioMedValley Discoveries
Pfizer
And others
Metastatic Uveal Melanoma Therapies covered in the report include:
Melphalan
Defacitinib (VS-6063) + VS-6766 (VH5126766)
Ulixertinib (BVD-523)
Binimetinib + Belinostat
And many others
Learn more about the emerging therapies & key companies in the Metastatic Uveal Melanoma Therapeutics Market @
https://www.delveinsight.com/report-store/metastatic-uveal-melanoma-mum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Uveal Melanoma Competitive Intelligence Analysis
4. Metastatic Uveal Melanoma Market Overview at a Glance
5. Metastatic Uveal Melanoma Disease Background and Overview
6. Metastatic Uveal Melanoma Patient Journey
7. Metastatic Uveal Melanoma Epidemiology and Patient Population
8. Metastatic Uveal Melanoma Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Uveal Melanoma Unmet Needs
10. Key Endpoints of Metastatic Uveal Melanoma Treatment
11. Metastatic Uveal Melanoma Marketed Products
12. Metastatic Uveal Melanoma Emerging Therapies
13. Metastatic Uveal Melanoma Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Uveal Melanoma Market Outlook (7 major markets)
16. Metastatic Uveal Melanoma Access and Reimbursement Overview
17. KOL Views on the Metastatic Uveal Melanoma Market.
18. Metastatic Uveal Melanoma Market Drivers
19. Metastatic Uveal Melanoma Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Get the Detailed TOC of the Metastatic Uveal Melanoma Market report here:
https://www.delveinsight.com/sample-request/metastatic-uveal-melanoma-mum-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
DelveInsight is a leading Life Science market research and business consulting company recognised for its off-the-shelf syndicated market research reports as well as customised solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Metastatic Uveal Melanoma Market to Observe Stupendous Growth During the Forecast Period - DelveInsight | Key Companies - Delcath Systems, Versastem Oncology, BioMedValley Discoveries, Pfizer, and Others here
News-ID: 2635235 • Views: …
More Releases from DelveInsight Business Research
Stuttering Market Positioned for Accelerated Development Through 2034, DelveInsi …
The Stuttering market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Stuttering pipeline products will significantly revolutionize the Stuttering market dynamics.
DelveInsight's "Stuttering Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Stuttering, historical and forecasted epidemiology as well as the Stuttering market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Acute Ischemic Stroke Pipeline 2025: Therapies, MOA Insights, and Key Clinical T …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Acute Ischemic Stroke pipeline constitutes 20+ key companies continuously working towards developing 25+ Acute Ischemic Stroke treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Acute Ischemic Stroke Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase.…
Insomnia Market to Expand Significantly by 2034, States DelveInsight Report
The Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Insomnia pipeline products will significantly revolutionize the Insomnia market dynamics.
DelveInsight's "Insomnia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Insomnia, historical and forecasted epidemiology as well as the Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the…
Global Clinical Trial Support Services Market to reach USD 43,160.56 million by …
According to DelveInsight's analysis, The clinical trial support services market is witnessing significant growth, driven by the increasing prevalence of chronic diseases such as diabetes, cancer, and cardiovascular disorders. This rise has resulted in a surge in clinical trial activities, higher R&D investments, and greater focus on drug development. Moreover, expanding collaborations between pharmaceutical, biotechnology, and medical device companies are boosting the need for specialized services, including regulatory assistance, data…
More Releases for Uveal
Uveal Neoplasms Market Detailed Industry Report Analysis 2025-2034
Introduction
Uveal neoplasms, also referred to as uveal melanomas and related tumors, are rare malignancies that arise from the uveal tract of the eye, which includes the iris, ciliary body, and choroid. Among these, uveal melanoma is the most common primary intraocular malignancy in adults. Despite its rarity, it carries high morbidity and mortality risks, especially when it metastasizes to the liver.
Traditional management strategies - including surgery, radiotherapy, and enucleation -…
Metastatic Uveal Melanoma Therapeutics Market: An In-Depth Analysis
The Metastatic Uveal Melanoma Therapeutics market was valued at USD 1.23 billion in 2023 and is projected to reach approximately USD 3.00 billion by 2033, growing at an estimated CAGR of around 8.9% from 2024 to 2033.
Metastatic Uveal Melanoma Therapeutics Market Overview
The Metastatic Uveal Melanoma Therapeutics market is evolving rapidly with the emergence of novel targeted and immunotherapeutic treatments addressing this rare and aggressive cancer. Increasing research into tumor-specific pathways…
Global Uveal Melanoma Treatment Market Will Generate Record Revenue by 2028
This Uveal Melanoma Treatment market report is the product of thorough market study and comments on important factors that influence financial decision. Here, helpful insights on customer demands are provided in order to launch the best product or service on the market. COVID-19's detrimental effects on the world economy system are also captured in this way. As a result of the pandemic, some businesses experienced considerable financial losses. Several businesses…
Uveal Melanoma Therapeutics- Clinical Trials & Results | HARMONIC PHARMA, Immuno …
Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body.
Download the sample report @ https://www.pharmaproff.com/request-sample/1121
The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia. The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy.
Get…
Uveal Melanoma Global Market Research Report 2025
Uveal Melanoma Report by Material, Application, and Geography � Global Forecast to 2022 is a professional and in-depth research report on the world's major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, united Kingdom, Japan, South Korea and China).
Access more details about this report at: https://www.research2reports.com/report-medical-devices/uveal-melanoma-market/80986
The report firstly introduced the Uveal Melanoma basics: definitions, classifications, applications and…
Uveal Melanoma Market By Analysis of Major Industry Segments 2024
Global Uveal Melanom Market: Overview
Uvea is present posterior to sclera and the cornea and has three parts namely, iris, ciliary body and choroid. Uveal melanoma is referred as the cancer of the parts of eye including the iris choroid and ciliray body. It is the condition in which the tumors arise from the melanocytes residing within the uva responsible for the color of the eye. Though is a rare…
